Robert Carlson

Clinical Focus

• Cancer > Breast Cancer
• Breast Cancer - Medical Oncology
• Oncology (Cancer)
• Medical Oncology

Professional Education

• Board Certification: Medical Oncology, American Board of Internal Medicine (1983)
• SUMC - Graduate Medical Education (1983) CA
• Board Certification: Internal Medicine, American Board of Internal Medicine (1981)
• SUMC - Graduate Medical Education (1981) CA
• Barnes Hospital (1980) MO
• Barnes Hospital (1979)
• Stanford University School of Medicine (1978) CA

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. 

• Consulting: Beta Healthcare Group RMA, Kaiser Foundation Health Plan, Inc, Pfizer, Inc

Current Research Interests

Clinical investigations in breast cancer include institutional and NSABP studies of chemoprevention, adjuvant therapy, psychosocial interventions, treatment of metastatic disease, methods of decreasing anthracycline cardiotoxicity, and modulation of multidrug resistance. Research in meta-analysis includes the performance of meta-analysis in a wide variety of settings in cancer treatment by the international Meta-Analysis Group in Cancer.

Computer science research efforts focus on computer-based systems for patient care. These include: the development of expert systems to assist in the care of patients with cancer (ONCOCIN) or AIDS (T-Helper); the development of computer-based systems using speech and pen-based input for medical records to access sources of medical knowledge; the design of three-dimensional methods of performing and representing literature searches; and the development of standards for implementing of medical computer-based systems; the development of smart agents and medical ontologies.

Clinical Trials

• A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer Recruiting
• Development of Vitamin D as a Therapy for Breast Cancer - Phase II Recruiting
• Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption Recruiting
• Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer Recruiting
• B-Receptor Signaling in Cardiomyopathy Recruiting
• Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer Recruiting
• Phase II Gemzar, Taxol & Avastin Combination as 1st Line Tx for Metastatic Breast CA Recruiting
• Phase II Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel with Lapatinib in Stage II/III Her2Neu+ Breast Cancer Recruiting
• Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Recruiting
• Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival Recruiting
• Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Recruiting
• Survey of Optical Measures of Breast Tissue in the Clinic Recruiting
• Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer Recruiting
• A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) No longer recruiting
• Anastrozole and Gefitinib Compared With Fulvestrant and Gefitinib in Treating Postmenopausal Women With Recurrent or Metastatic Breast Cancer No longer recruiting
• Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Suspended
• Estradiol Suppression for the treatment of metastatic breast cancer in premenopausal women No longer recruiting
• A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer No longer recruiting
• Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer No longer recruiting
• Intellectual Impairment in Women With Breast Cancer Not yet recruiting

Publications

• Rational Surveillance Programs for Early Stage Breast Cancer Patients After Primary Treatment. Mollick JA,  Carlson RW.  Breast Dis.  2009; 21 47-54
• First-line chemotherapy for metastatic breast cancer. Telli ML,  Carlson RW.  Clin Breast Cancer.  2009; 9 Suppl 2 S66-72
• Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. Svahn TH,  Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, Edge SB, Schott AF, Bookman MA, Weeks JC.  J Natl Compr Canc Netw.  2009; 7 (2): 115-21
• The decline in breast cancer incidence: real or imaginary? Kurian AW,  Clarke CA, Carlson RW.  Curr Oncol Rep.  2009; 11 (1): 21-8
• Selecting high priority quality measures for breast cancer quality improvement. Hassett MJ,  Hughes ME, Niland JC, Ottesen R, Edge SB, Bookman MA, Carlson RW, Theriault RL, Weeks JC.  Med Care.  2008; 46 (8): 762-70
• Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Telli ML,  Horst KC, Guardino AE, Dirbas FM, Carlson RW.  J Natl Compr Canc Netw.  2007; 5 (3): 324-30
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. Telli ML,  Hunt SA, Carlson RW, Guardino AE.  J Clin Oncol.  2007; 25 (23): 3525-33
• Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Spiegel D,  Butler LD, Giese-Davis J, Koopman C, Miller E, DiMiceli S, Classen CC, Fobair P, Carlson RW, Kraemer HC.  Cancer.  2007; 110 (5): 1130-8
• NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Carlson RW,  Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC.  J Natl Compr Canc Netw.  2006; 4 Suppl 1 S1-26
• HER2 testing in breast cancer: NCCN Task Force report and recommendations. Carlson RW,  Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM.  J Natl Compr Canc Netw.  2006; 4 Suppl 3 S1-22; quiz S23-4
• Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Chan JK,  Manuel MR, Cheung MK, Osann K, Husain A, Teng NN, Rao A, Carlson RW, Whittemore AS.  Gynecol Oncol.  2006; 102 (3): 508-12
• A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Carlson RW,  O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC.  Cancer Invest.  2006; 24 (7): 677-81
• Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. Carlson RW,  Hudis CA, Pritchard KI.  J Natl Compr Canc Netw.  2006; 4 (10): 971-9
• Update: NCCN breast cancer Clinical Practice Guidelines. Carlson RW,  McCormick B.  J Natl Compr Canc Netw.  2005; 3 Suppl 1 S7-11
• The history and mechanism of action of fulvestrant. Carlson RW,  Clin Breast Cancer.  2005; 6 Suppl 1 S5-8
• Breast cancer. Carlson RW,  Anderson BO, Burstein HJ, Cox CE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis C, Jahanzeb M, Ljung BM, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC.  J Natl Compr Canc Netw.  2005; 3 (3): 238-89
• Predictors of local recurrence after breast-conservation therapy. Horst KC,  Smitt MC, Goffinet DR, Carlson RW.  Clin Breast Cancer.  2005; 5 (6): 425-38
• Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know? Chung CT,  Carlson RW.  Clin Breast Cancer.  2004; 5 Suppl 1 S18-23
• High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer. Carlson RW,  Wheatley K.  Cancer Treat Rev.  2004; 30 (1): 131-7
• Rational surveillance programs for early stage breast cancer patients after primary treatment. Mollick JA,  Carlson RW.  Breast Dis.  2004; 21 47-54
• Treatment of breast cancer in countries with limited resources. Carlson RW,  Anderson BO, Chopra R, Eniu AE, Jakesz R, Love RR, Masetti R, Schwartsmann G.  Breast J.  2003 May-Jun; 9 Suppl 2 S67-74
• Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. Hartman AR,  Grekowicz A, Lum BL, Carlson RW, Schurman C, Sikic BI, Shapiro R, Stockdale FE.  Breast Cancer Res Treat.  2003; 82 (1): 61-9
• The role of aromatase inhibitors in early breast cancer. Chung CT,  Carlson RW.  Curr Treat Options Oncol.  2003; 4 (2): 133-40
• Goals and objectives in the management of metastatic breast cancer. Chung CT,  Carlson RW.  Oncologist.  2003; 8 (6): 514-20
• Predictors of reexcision findings and recurrence after breast conservation. Smitt MC,  Nowels K, Carlson RW, Jeffrey SS.  Int J Radiat Oncol Biol Phys.  2003; 57 (4): 979-85
• Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Carlson RW,  Henderson IC.  Breast Cancer Res Treat.  2003; 80 Suppl 1 S19-26; discussion S27-8
• Sequencing of endocrine therapies in breast cancer--integration of recent data. Carlson RW,  Breast Cancer Res Treat.  2002; 75 Suppl 1 S27-32; discussion S33-5
• NCCN: Breast cancer. Carlson RW,  Edge SB, Theriault RL.  Cancer Control.  2001 Nov-Dec; 8 (6 Suppl 2): 54-61
• Locally advanced breast cancer: is surgery necessary? Favret AM,  Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE.  Breast J.  2001 Mar-Apr; 7 (2): 131-7
• Supportive-expressive group therapy and distress in patients with metastatic breast cancer: a randomized clinical intervention trial. Classen C,  Butler LD, Koopman C, Miller E, DiMiceli S, Giese-Davis J, Fobair P, Carlson RW, Kraemer HC, Spiegel D.  Arch Gen Psychiatry.  2001; 58 (5): 494-501
• NCCN Practice Guidelines for Breast Cancer. Carlson RW,  Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A.  Oncology (Williston Park).  2000; 14 (11A): 33-49
• Management of breast cancer after Hodgkin's disease. Wolden SL,  Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT.  J Clin Oncol.  2000; 18 (4): 765-72
• New bilateral microcalcifications at mammography in a postlactational woman: case report. Stucker DT,  Ikeda DM, Hartman AR, George TI, Nowels KW, Birdwell SL, Goffinet D, Carlson RW.  Radiology.  2000; 217 (1): 247-50
• Multidisciplinary Management of Locally Advanced Breast Cancer. Carlson RW,  Favret AM.  Breast J.  1999; 5 (5): 303-307
• Quality of life issues in the treatment of metastatic breast cancer. Carlson RW,  Oncology (Williston Park).  1998; 12 (3 Suppl 4): 27-31
• Scientific review of tamoxifen. Overview from a medical oncologist. Carlson RW,  Semin Oncol.  1997; 24 (1 Suppl 1): S1-151-S1-7
• Effects of medical and psychotherapeutic treatment on the survival of women with metastatic breast carcinoma. Kogon MM,  Biswas A, Pearl D, Carlson RW, Spiegel D.  Cancer.  1997; 80 (2): 225-30
• NCCN Breast Cancer Practice Guidelines. The National Comprehensive Cancer Network. Carlson RW,  Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Moe RE, Theriault RL.  Oncology (Williston Park).  1996; 10 (11 Suppl): 47-75
• Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer Piedbois P,  Buyse M, Kemeny N, Rougier P, Carlson R, Allen-Mersh T, O'Connel M, Change A, Sondak V, Kemeny M, Levy.  Journal of the National Cancer Institute.  1996; 88 252-258
• Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. Hillner BE,  Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD.  J Clin Oncol.  1996; 14 (1): 70-7
• The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Smitt MC,  Nowels KW, Zdeblick MJ, Jeffrey S, Carlson RW, Stockdale FE, Goffinet DR.  Cancer.  1995; 76 (2): 259-67
• Computer-based screening of patients with HIV/AIDS for clinical-trial eligibility. Carlson RW,  Tu SW, Lane NM, Lai TL, Kemper CA, Musen MA, Shortliffe EH.  Online J Curr Clin Trials.  1995; Doc No 179 [3347 words; 32 paragraphs]
• Toward a patient-centered knowledge-server standard for CPRs. Tuttle MS,  Sheretz DD, Fagan LM, Carlson RW, Cole WG, Schipma PB, Nelson SJ..  Proceedings of the 1994 Annual Healthcare Information and Management Systems Society Conference.  1994; 88 114-128
• Integration of pen-based computer technology in clinical settings. Acuff RD,  Fagan LM, Rindfleisch TC, Carlson RW, Tuttle MS, Sherertz DD.  Proc Annu Symp Comput Appl Med Care.  1994; 1042
• A methodology for determining patients' eligibility for clinical trials. Tu SW,  Kemper CA, Lane NM, Carlson RW, Musen MA.  Methods Inf Med.  1993; 32 (4): 317-25
• Impact of omeprazole on the plasma clearance of methotrexate. Reid T,  Yuen A, Catolico M, Carlson RW.  Cancer Chemother Pharmacol.  1993; 33 (1): 82-4
• T-HELPER: automated support for community-based clinical research. Musen MA,  Carlson RW, Fagan LM, Deresinski SC, Shortliffe EH.  Proc Annu Symp Comput Appl Med Care.  1992; 719-23
• Reducing the cardiotoxicity of the anthracyclines. Carlson RW,  Oncology (Williston Park).  1992; 6 (6): 95-100, 104, 107, discussion 107-8
• Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Carlson RW,  Sikic BI, Gandara DR, Hendrickson CG, Wittlinger PS, Shields JA, Wong PP, White JE, Meakin CJ, McWhirter KM.  Cancer.  1991; 68 (5): 948-58
• Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group. Carlson RW,  Doroshow JH, Odujinrin OO, Flam MS, Malec M, Lamborn KR.  Invest New Drugs.  1990; 8 (4): 387-9
• A phase II trial of carbetimer for the treatment of colorectal cancer. A trial of the Northern California Oncology Group. Audeh MW,  Jacobs CD, Davis TE, Carlson RW.  Am J Clin Oncol.  1990; 13 (4): 324-6
• A multiinstitutional evaluation of the analgesic efficacy and safety of ketorolac tromethamine, acetaminophen plus codeine, and placebo in cancer pain. Carlson RW,  Borrison RA, Sher HB, Eisenberg PD, Mowry PA, Wolin EM.  Pharmacotherapy.  1990; 10 (3): 211-6
• Successful treatment of metastatic thymic carcinoma with cisplatin, vinblastine, bleomycin, and etoposide chemotherapy. Carlson RW,  Dorfman RF, Sikic BI.  Cancer.  1990; 66 (10): 2092-4
• The clinical biology of breast cancer. Carlson RW,  Stockdale FE.  Annu Rev Med.  1988; 39 453-64
• Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. Coleman CN,  Carlson RW, Artim RA, Sampson WI, Lawrence HJ, Wong P, Halsey J, Kohler M, Gribble M, Sikic BI.  Cancer Res.  1988; 48 (12): 3528-32
• Combined modality therapy of locally advanced breast cancer. One institution's experience and a review of the literature. Hu E,  Stockdale FE, Turner B, Carlson RW, Levine J, Kushlan P.  Anticancer Res.  1987 Jul-Aug; 7 (4B): 733-6
• Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study. Tan YO,  Hendrickson C, McWhirter K, Kohler M, Hannigan JF, Carlson RW.  Cancer Treat Rep.  1987; 71 (10): 969-70